The most common [[adverse effect|side effect]] seen is [[constipation]] (2-3%). Less commonly reported side effects (<0.5%) include [[flatulence]], [[headache]], [[hypophosphatemia]], [[xerostomia]] (dry mouth), and [[bezoar]] formation.<ref>http://medsfacts.com/study-SUCRALFATE-causing-BEZOAR.php</ref><ref>{{Cite web|url = http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018333s034,019183s016lbl.pdf|title = Carafate Package Insert|date = September 12, 2013|accessdate = November 2, 2015|website = |publisher = |last = |first = }}</ref><ref>{{Cite journal|title = ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998|journal = American Journal of Health-System Pharmacy|date = 1999-02-15|issn = 1079-2082|pmid = 10690219|pages = 347–379|volume = 56|issue = 4}}</ref>

 
Avoid using this drug in people with [[chronic renal failure|chronic kidney failure]], as it might cause aluminium accumulation and [[Aluminium toxicity in dialysis patients|toxicity]].

 
There is a limited number of well-controlled studies investigating the safety and efficacy of sucralfate in children and pregnant women ([[Pregnancy Category]] B).<ref name=":3"/><ref>{{Cite journal|title = Interventions for heartburn in pregnancy|journal = The Cochrane Database of Systematic Reviews|date = 2015-01-01|issn = 1469-493X|pmid = 26384956|pages = CD011379|volume = 9|doi = 10.1002/14651858.CD011379.pub2|first = Vorapong|last = Phupong|first2 = Tharangrut|last2 = Hanprasertpong}}</ref><ref name=":0">{{Cite journal|title = Sucralfate: pharmacokinetics, metabolism and selective binding to experimental gastric and duodenal ulcers in animals|journal = Arzneimittel-Forschung|date = 1982-01-01|issn = 0004-4172|pmid = 6896647|pages = 512–518|volume = 32|issue = 5|first = K.|last = Steiner|first2 = K. U.|last2 = Bühring|first3 = H. P.|last3 = Faro|first4 = A.|last4 = Garbe|first5 = H.|last5 = Nowak}}</ref>

 

